- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05415917
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Primary Objectives:
To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone.
Secondary Objectives:
To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS).
To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates.
To assess the quality of life in patients receiving the study treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Howard S Hochster, MD
- Phone Number: 732-235-2465
- Email: howard.hochster@rutgers.edu
Study Contact Backup
- Name: Prateek Gulhati, MD, PhD
- Phone Number: 732-235-2465
- Email: pat.gulhati@rutgers.edu
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Recruiting
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Prateek Gulhati, MD
- Phone Number: 732-253-5618
- Email: pat.gulhati@rutgers.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically and/or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma
- Neoadjuvant chemotherapy (for at least three months) ± chemoradiation followed by R0 surgical resection
- Eastern Cooperative Oncology Group(ECOG) Performance status of PS 0 - 2
- At least 18 years of age
Adequate bone marrow and organ functions as defined by:
- Absolute neutrophil count ≥ 1000 cells/ μL
- Hemoglobin ≥ 8 g/ dL
- Platelets > 75,000 / μL
- Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
- Total bilirubin ≤1.5 ULN
- AST/ ALT < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
- Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately
- Ability to understand the nature of this study protocol and give written informed consent.
- Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures
Exclusion Criteria:
- Receipt of any investigational agents at the time of registration
- Known, untreated brain metastases
- Presence of metastatic disease or malignant ascites on diagnostic imaging
- Grade two or greater peripheral neuropathy
- Presence of any additional active malignancy within the past 3 years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
- Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure (NYHA classification grade III or IV), unstable angina or active arrhythmia
- Major surgery within the 4 weeks prior to initiation of study treatment
- A history of allergy or hypersensitivity to any of the study drugs
- Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
- Pregnancy
- Severe hepatic impairment
- Participants with known malabsorption
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1- Gemcitabine and Capecitabine Treatment
Day 1, Day 8, Day 15 • Gemcitabine infused through a vein over 120 minutes Day 1 - Day 21 • Capecitabine tablets will be taken two times a day; once in the morning and once in the evening. The tablets should not be crushed or split and should be taken with a full glass of water (8 ounces/240 milliliters) within 30 minutes after a meal. |
A chemotherapy cycle will constitute 28 days of treatment:
|
No Intervention: Group 2 - Observational
Usual therapy used to treat this type of cancer, chemotherapy plus radiation therapy.
If cancer returns during observation, there will be offered standard of care therapy.
Follow-up visits will be every three months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by number of participants experiencing adverse events
Time Frame: Five Years
|
Number of participants experiencing adverse events as defined by Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) Version 5.0 for toxicity
|
Five Years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure the tumor with the Response Evaluation Criteria in Solid Tumors (RECIST)
Time Frame: Five Years
|
Response and progression will be evaluated in this study using the international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1), when possible eleven Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used for tumor measurements.
Imaging for response assessment will be obtained before the initiation of conditioning and at the six-week follow up time point.
|
Five Years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Prateek Gulhati, MD, PhD, Rutgers Cancer Institute of New Jersey
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
- Gemcitabine
Other Study ID Numbers
- CINJ 072206
- Pro2022000669 (Other Identifier: Rutgers, The State University of New Jersey)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
Clinical Trials on Gemcitabine and Capecitabine
-
Assiut UniversityNot yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.TerminatedTriple Negative Breast CancerChina
-
NCIC Clinical Trials GroupTerminatedLiver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct CancerCanada
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Dorte NielsenCompletedCholangiocarcinomaDenmark
-
Vejle HospitalCompletedCholangiocarcinomaDenmark
-
Swiss Group for Clinical Cancer ResearchCentral European Cooperative Oncology GroupCompletedPancreatic CancerSwitzerland, Italy, Israel, Austria
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Recruiting
-
Centro Nacional de Investigaciones Oncologicas...Apices Soluciones S.L.; Hospital Universitario de Fuenlabrada; Grupo Hospital...CompletedAdvanced Pancreatic CarcinomaSpain
-
Klinikum der Universitaet Muenchen, GrosshadernLudwig-Maximilians - University of Munich; The European Society for Hyperthermic...Unknown